DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Read More…
Industry, Sector and Symbol
Industry Dental equipment & supplies
Sub-IndustryHealth Care Supplies
SectorMedical
Phone844-546-3722
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.99 billion
Profitability
Miscellaneous
Employees16,400
Next Earnings Date3/6/2020 (Estimated)
OptionableOptionable
DENTSPLY SIRONA (NASDAQ:XRAY) Frequently Asked Questions
What is DENTSPLY SIRONA's stock symbol?
DENTSPLY SIRONA trades on the NASDAQ under the ticker symbol "XRAY."
How often does DENTSPLY SIRONA pay dividends? What is the dividend yield for DENTSPLY SIRONA?
DENTSPLY SIRONA declared a quarterly dividend on Friday, December 13th. Shareholders of record on Friday, December 27th will be given a dividend of $0.10 per share on Friday, January 10th. This represents a $0.40 dividend on an annualized basis and a yield of 0.67%. The ex-dividend date of this dividend is Thursday, December 26th. View DENTSPLY SIRONA's Dividend History.
How were DENTSPLY SIRONA's earnings last quarter?
DENTSPLY SIRONA Inc (NASDAQ:XRAY) announced its earnings results on Thursday, November, 7th. The medical instruments supplier reported $0.57 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.50 by $0.07. The medical instruments supplier earned $962.10 million during the quarter, compared to analyst estimates of $940.38 million. DENTSPLY SIRONA had a net margin of 4.08% and a return on equity of 10.08%. The business's revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.38 EPS. View DENTSPLY SIRONA's Earnings History.
When is DENTSPLY SIRONA's next earnings date?
What guidance has DENTSPLY SIRONA issued on next quarter's earnings?
DENTSPLY SIRONA updated its FY19 earnings guidance on Thursday, November, 7th. The company provided earnings per share (EPS) guidance of $2.42-2.48 for the period, compared to the Thomson Reuters consensus estimate of $2.39. The company issued revenue guidance of $3.95-4.05 billion, compared to the consensus revenue estimate of $3.99 billion.
What price target have analysts set for XRAY?
10 analysts have issued 12 month target prices for DENTSPLY SIRONA's stock. Their forecasts range from $49.00 to $65.00. On average, they anticipate DENTSPLY SIRONA's share price to reach $56.41 in the next year. This suggests that the stock has a possible downside of 5.9%. View Analyst Price Targets for DENTSPLY SIRONA.
What is the consensus analysts' recommendation for DENTSPLY SIRONA?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DENTSPLY SIRONA in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for DENTSPLY SIRONA.
What are Wall Street analysts saying about DENTSPLY SIRONA stock?
Here are some recent quotes from research analysts about DENTSPLY SIRONA stock:
- 1. According to Zacks Investment Research, "DENTSPLY ended the third quarter on a solid note. Significant increase in the bottom line bodes well. The company gained from its core Technology & Equipment unit that witnessed year-over-year upside in the quarter. Overall sales grew on an internal basis. Internationally, revenues surged as well. The company raised earnings per share guidance, which indicates bright prospects. Product launches are encouraging. Significant expansion in margins is another positive. The stock has outperformed the industry in a year. Meanwhile, sales of Restorative and Endodontics products as well as Laboratory Dental products witnessed some softness in the quarter. Additionally, unfavorable foreign currency exchange and restructuring costs are expected to exert pressure on DENTSPLY SIRONA’s top line in 2019. The stock is overvalued at the moment." (12/10/2019)
- 2. Barrington Research analysts commented, "We are now modeling $2.35, up from our prior $2.32 estimate." (8/5/2019)
Has DENTSPLY SIRONA been receiving favorable news coverage?
Media headlines about XRAY stock have trended negative this week, InfoTrie reports. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. DENTSPLY SIRONA earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news coverage about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for DENTSPLY SIRONA.
Are investors shorting DENTSPLY SIRONA?
DENTSPLY SIRONA saw a decrease in short interest in December. As of December 31st, there was short interest totalling 3,540,000 shares, a decrease of 17.1% from the December 15th total of 4,270,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently 2.7 days. Currently, 1.6% of the company's shares are short sold. View DENTSPLY SIRONA's Current Options Chain.
Who are some of DENTSPLY SIRONA's key competitors?
Some companies that are related to DENTSPLY SIRONA include Align Technology (ALGN), Cooper Companies (COO), West Pharmaceutical Services (WST), Haemonetics (HAE), ICU Medical (ICUI), Neogen (NEOG), Quidel (QDEL), Merit Medical Systems (MMSI), STAAR Surgical (STAA), Atrion (ATRI), Antares Pharma (ATRS), Anika Therapeutics (ANIK), Cerus (CERS), OraSure Technologies (OSUR) and Meridian Bioscience (VIVO).
What other stocks do shareholders of DENTSPLY SIRONA own?
Who are DENTSPLY SIRONA's key executives?
DENTSPLY SIRONA's management team includes the folowing people:
- Mr. Nicholas William Alexos, Exec. VP & CFO (Age 55)
- Mr. Keith John Ebling, EVP, Gen. Counsel & Sec. (Age 50)
- Ms. Maureen J. MacInnis, Sr. VP, Chief HR Officer & Communications (Age 58)
- Mr. Donald M. Casey Jr., CEO & Director (Age 59)
- Mr. Dominique P. Legros, Sr. VP of Equipment, Technologies & Healthcare Segment (Age 59)
Who are DENTSPLY SIRONA's major shareholders?
DENTSPLY SIRONA's stock is owned by a number of of retail and institutional investors. Top institutional investors include Boston Trust Walden Corp (0.24%), Commerzbank Aktiengesellschaft FI (0.09%), State of Alaska Department of Revenue (0.06%), Tocqueville Asset Management L.P. (0.05%), Clean Yield Group (0.05%) and Stonebridge Capital Management Inc. (0.04%). Company insiders that own DENTSPLY SIRONA stock include Betsy D Holden, Daniel P Key, Donald M Jr Casey, Eric Brandt, Gregory T Lucier, Markus Boehringer, Maureen J Macinnis, Michael C Alfano, Michael J Coleman, Nicholas W Alexos and William E Newell. View Institutional Ownership Trends for DENTSPLY SIRONA.
Which institutional investors are selling DENTSPLY SIRONA stock?
XRAY stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Clean Yield Group, IFM Investors Pty Ltd, M&R Capital Management Inc., Welch & Forbes LLC, Tributary Capital Management LLC and Gateway Investment Advisers LLC. Company insiders that have sold DENTSPLY SIRONA company stock in the last year include Eric Brandt, Markus Boehringer, Maureen J Macinnis, Michael C Alfano, Michael J Coleman and William E Newell. View Insider Buying and Selling for DENTSPLY SIRONA.
Which institutional investors are buying DENTSPLY SIRONA stock?
XRAY stock was purchased by a variety of institutional investors in the last quarter, including Tocqueville Asset Management L.P., Boston Trust Walden Corp, Bowling Portfolio Management LLC, State of Alaska Department of Revenue, Assenagon Asset Management S.A., Commerzbank Aktiengesellschaft FI, Courier Capital LLC and First Hawaiian Bank. Company insiders that have bought DENTSPLY SIRONA stock in the last two years include Betsy D Holden, Daniel P Key, Donald M Jr Casey, Gregory T Lucier and Nicholas W Alexos. View Insider Buying and Selling for DENTSPLY SIRONA.
How do I buy shares of DENTSPLY SIRONA?
Shares of XRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is DENTSPLY SIRONA's stock price today?
One share of XRAY stock can currently be purchased for approximately $59.96.
How big of a company is DENTSPLY SIRONA?
DENTSPLY SIRONA has a market capitalization of $13.34 billion and generates $3.99 billion in revenue each year. The medical instruments supplier earns $-1,011,000,000.00 in net income (profit) each year or $2.01 on an earnings per share basis. DENTSPLY SIRONA employs 16,400 workers across the globe.View Additional Information About DENTSPLY SIRONA.
What is DENTSPLY SIRONA's official website?
How can I contact DENTSPLY SIRONA?
DENTSPLY SIRONA's mailing address is 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC, 28277. The medical instruments supplier can be reached via phone at 844-546-3722 or via email at [email protected]
MarketBeat Community Rating for DENTSPLY SIRONA (NASDAQ XRAY)
MarketBeat's community ratings are surveys of what our community members think about DENTSPLY SIRONA and other stocks. Vote "Outperform" if you believe XRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XRAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
